HK1079435A1 - Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy - Google Patents

Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy

Info

Publication number
HK1079435A1
HK1079435A1 HK05111475A HK05111475A HK1079435A1 HK 1079435 A1 HK1079435 A1 HK 1079435A1 HK 05111475 A HK05111475 A HK 05111475A HK 05111475 A HK05111475 A HK 05111475A HK 1079435 A1 HK1079435 A1 HK 1079435A1
Authority
HK
Hong Kong
Prior art keywords
nephropathy
fro
medicaments
preparations
treatment
Prior art date
Application number
HK05111475A
Other languages
English (en)
Inventor
Schaefer Stefan
Linz Wolfgang
Bleich Markus
Huber Jochen
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1079435A1 publication Critical patent/HK1079435A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK05111475A 2002-06-28 2005-12-14 Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy HK1079435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (1)

Publication Number Publication Date
HK1079435A1 true HK1079435A1 (en) 2006-04-07

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111475A HK1079435A1 (en) 2002-06-28 2005-12-14 Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy

Country Status (39)

Country Link
US (2) US6930103B2 (sl)
EP (1) EP1519732B1 (sl)
JP (1) JP4564354B2 (sl)
KR (1) KR101072235B1 (sl)
CN (1) CN100366254C (sl)
AR (1) AR040343A1 (sl)
AT (1) ATE548040T1 (sl)
AU (1) AU2003280440B2 (sl)
BR (1) BR0312250A (sl)
CA (1) CA2490277C (sl)
CR (1) CR7667A (sl)
CY (1) CY1112905T1 (sl)
DE (1) DE10229180A1 (sl)
DK (1) DK1519732T3 (sl)
EC (1) ECSP045513A (sl)
ES (1) ES2383889T3 (sl)
HK (1) HK1079435A1 (sl)
HN (1) HN2003000193A (sl)
HR (1) HRP20041212B1 (sl)
IL (2) IL165935A0 (sl)
MA (1) MA27281A1 (sl)
MX (1) MXPA04012230A (sl)
NO (1) NO334811B1 (sl)
NZ (1) NZ537480A (sl)
OA (1) OA12871A (sl)
PA (1) PA8576501A1 (sl)
PE (1) PE20040582A1 (sl)
PL (1) PL218070B1 (sl)
PT (1) PT1519732E (sl)
RS (1) RS52478B (sl)
RU (1) RU2336080C2 (sl)
SI (1) SI1519732T1 (sl)
SV (1) SV2004001560A (sl)
TN (1) TNSN04262A1 (sl)
TW (1) TWI326215B (sl)
UA (1) UA82845C2 (sl)
UY (1) UY27869A1 (sl)
WO (1) WO2004002492A1 (sl)
ZA (1) ZA200409382B (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP2558208B2 (ja) * 1991-03-01 1996-11-27 ゼリア新薬工業株式会社 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
ES2117123T3 (es) * 1992-02-14 1998-08-01 Merrell Pharma Inc Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) * 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
DE69630465T2 (de) 1995-12-27 2004-07-22 Mitsubishi Pharma Corp. Vorsorge-/heilmittel fur die komplikationen von diabetes
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
MXPA03008613A (es) * 2001-04-12 2003-12-08 Aventis Pharma Gmbh Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso.
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
AU2003280440B2 (en) 2009-07-16
ES2383889T3 (es) 2012-06-27
MXPA04012230A (es) 2005-02-25
TNSN04262A1 (en) 2007-03-12
PT1519732E (pt) 2012-05-22
WO2004002492A1 (en) 2004-01-08
IL165935A0 (en) 2006-01-15
US20040058911A1 (en) 2004-03-25
ECSP045513A (es) 2005-03-10
OA12871A (en) 2006-09-15
SV2004001560A (es) 2004-02-26
CN1665512A (zh) 2005-09-07
CY1112905T1 (el) 2016-04-13
EP1519732A1 (en) 2005-04-06
NO334811B1 (no) 2014-06-02
SI1519732T1 (sl) 2012-05-31
US20050171090A1 (en) 2005-08-04
US6930103B2 (en) 2005-08-16
HRP20041212B1 (hr) 2013-06-30
PL372992A1 (en) 2005-08-08
DK1519732T3 (da) 2012-06-18
MA27281A1 (fr) 2005-04-01
UY27869A1 (es) 2003-12-31
RS100704A (en) 2007-02-05
DE10229180A1 (de) 2004-01-29
NZ537480A (en) 2005-11-25
IL165935A (en) 2010-12-30
JP4564354B2 (ja) 2010-10-20
KR20050013642A (ko) 2005-02-04
TWI326215B (en) 2010-06-21
CA2490277C (en) 2011-11-01
TW200406214A (en) 2004-05-01
HN2003000193A (es) 2004-10-27
CN100366254C (zh) 2008-02-06
HRP20041212A2 (en) 2005-06-30
RS52478B (en) 2013-02-28
PL218070B1 (pl) 2014-10-31
ATE548040T1 (de) 2012-03-15
KR101072235B1 (ko) 2011-10-12
CA2490277A1 (en) 2004-01-08
AR040343A1 (es) 2005-03-30
NO20050425L (no) 2005-01-25
PA8576501A1 (es) 2004-02-07
JP2005533815A (ja) 2005-11-10
BR0312250A (pt) 2005-04-26
PE20040582A1 (es) 2004-10-18
UA82845C2 (en) 2008-05-26
US7514423B2 (en) 2009-04-07
CR7667A (es) 2005-06-16
RU2336080C2 (ru) 2008-10-20
RU2005102087A (ru) 2005-07-10
EP1519732B1 (en) 2012-03-07
AU2003280440A1 (en) 2004-01-19
ZA200409382B (en) 2006-01-25

Similar Documents

Publication Publication Date Title
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL172316A0 (en) Novel compounds and their use in therapy
AU2003265225A8 (en) Preparations for topical skin use and treatment
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
HK1162948A1 (zh) 哈米特林 衍生物及其在治療癌症中的應用
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
GB0324761D0 (en) Use of compounds in therapy
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
ZA200410401B (en) Use of thio-oxindole derivatives in treatment of skin disorders
GB0207411D0 (en) Azole compounds and their therapeutic use
SI1197485T1 (sl) Derivati ciklobuten-diona in njihova uporaba pri zdravljenju arterioskleroze
SG110107A1 (en) Compound and use in treatment
HK1079435A1 (en) Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
IL175774A0 (en) Use of siramesine in the treatment of cancer
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
IL174968A0 (en) The use of ifenprodil in the treatment of pain

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20060407: [71] SANOFI-AVENTIS DEUTSCHLAND GMBH - D-65929FRANKFURT AM MAIN - GERMANY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150613